{"organizations": [], "uuid": "a1d4534905ee8c0c711d909be417f6cac2ffeff4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/brief-amgen-reports-aimovig-met-all-prim/brief-amgen-reports-aimovig-met-all-primary-secondary-endpoints-idUSFWN1PH13K", "country": "US", "domain_rank": 408, "title": "BRIEF-Amgen Reports Aimovig Met All Primary, Secondary Endpoints", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-23T06:02:00.000+02:00", "replies_count": 0, "uuid": "a1d4534905ee8c0c711d909be417f6cac2ffeff4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-amgen-reports-aimovig-met-all-prim/brief-amgen-reports-aimovig-met-all-primary-secondary-endpoints-idUSFWN1PH13K", "ord_in_thread": 0, "title": "BRIEF-Amgen Reports Aimovig Met All Primary, Secondary Endpoints", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "amgen inc", "sentiment": "negative"}, {"name": "amgen", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "novartis", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 22 (Reuters) - Amgen Inc:\n* AMGEN REPORTS AIMOVIGâ„¢ (ERENUMAB) MET ALL PRIMARY AND SECONDARY ENDPOINTS IN UNIQUE PHASE 3B STUDY IN EPISODIC MIGRAINE PATIENTS WHO HAVE FAILED MULTIPLE PRIOR PREVENTIVE TREATMENTS\n* AMGEN INC - FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF MAY 17, 2018\n* AMGEN INC - IF APPROVED, NOVARTIS AND AMGEN WILL CO-COMMERCIALIZE AIMOVIG IN U.S.\n* AMGEN INC - SAFETY DATA ARE CONSISTENT WITH PREVIOUS STUDIES OF AIMOVIG TO DATE\n* AMGEN INC - LIBERTY ALSO MET ALL SECONDARY ENDPOINTS, INCLUDING REDUCTION OF MONTHLY MIGRAINE DAYS, REDUCTION IN DAYS NEEDING ACUTE MEDICATION Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-23T06:02:00.000+02:00", "crawled": "2018-01-23T07:40:41.000+02:00", "highlightTitle": ""}